Suitability of a new antimicrobial aminosterol formulation for aerosol delivery in cystic fibrosis

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 12, 2011, Pages 2797-2800

  Alhanout, Kamel ^a   Brunel, Jean Michel ^a   Dubus, Jean Christophe ^a   Rolain, Jean Marc ^a   Andrieu, Véronique ^a  

^a AIX MARSEILLE UNIVERSITÉ   (France)

Author keywords

Infections; Nebulizers; Squalamine

Indexed keywords

AMINOSTEROL DERIVATIVE; ANTIBIOTIC AGENT; ISOTONIC SOLUTION; SODIUM CHLORIDE; SODIUM HYDROXIDE; STEROL DERIVATIVE; TOBRAMYCIN; UNCLASSIFIED DRUG;

AEROSOL; ANTIBACTERIAL ACTIVITY; ARTICLE; BROTH DILUTION; CONTROLLED STUDY; CYSTIC FIBROSIS; IN VITRO STUDY; INHALATION; LASER DIFFRACTION; LUNG INFECTION; MINIMUM INHIBITORY CONCENTRATION; NEBULIZER; NONHUMAN; OSMOLARITY; PARTICLE SIZE; PH; PHYSICAL CHEMISTRY; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

AEROSOLS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CHOLESTANOLS; CYSTIC FIBROSIS; DRUG STABILITY; HUMANS; MICROBIAL SENSITIVITY TESTS; PARTICULATE MATTER; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

EID: 81855199771     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr380     Document Type: Article

References (10)

1. Alhanout K, Brunel JM, Raoult D et al. In vitro antibacterial activity of aminosterols against multidrug-resistant bacteria from patients with cystic fibrosis. J Antimicrob Chemother 2009; 64: 810-4.
2. Guy EL, Bosomworth M, Denton M et al. Serum tobramycin levels following delivery of tobramycin (Tobi) via eFlow advanced nebuliser in children with cystic fibrosis. J Cyst Fibros 2010; 9: 292-5.
3. Hubert D, Leroy S, Nove-Josserand R et al. Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis. J Cyst Fibros 2009; 8: 332-7.
4. Rottier BL, van Erp CJ, Sluyter TS et al. Changes in performance of the Pari eFlow rapid and Pari LC Plus during 6 months use by CF patients. J Aerosol Med Pulm Drug Deliv 2009; 22: 263-9.
5. Ramphal R, Lhermitte M, Filliat M et al. The binding of anti-pseudomonal antibiotics to macromolecules from cystic fibrosis sputum. J Antimicrob Chemother 1988; 22: 483-90.
6. Alhanout K, Rolain JM, Brunel JM. Squalamine as an example of a new potent antimicrobial agents class: a critical review. Curr Med Chem 2010; 17: 3909-17.
7. Bucki R, Namiot DB, Namiot Z et al. Salivary mucins inhibit antibacterial activity of the cathelicidin-derived LL-37 peptide but not the cationic steroid CSA-13. J Antimicrob Chemother 2008; 62: 329-35.
8. Clarck A. The use of laser diffraction for the evaluation of the aerosol clouds generated by medical nebulizers. Int J Pharm 1995; 115: 69-78.
9. Wong-Beringer A, Lambros MP, Beringer PM et al. Suitability of caspofungin for aerosol delivery: physicochemical profiling and nebulizer choice. Chest 2005; 128: 3711-6.
10. Pilcer G, Vanderbist F, Amighi K. Correlations between cascade impactor analysis and laser diffraction techniques for the determination of the particle size of aerosolised powder formulations. Int J Pharm 2008; 358: 75-81.